BCL2 and melanoma: Delivered to cells gynomically (i.e., without conjugates or transfectants), it was efficiently internalized by a range of cell lines (melanoma, lymphoma and fibrosarcoma) and was more potent than Oblimersen at reducing Bcl-2 expression [86].